Kirkland Assists Ascletis Pharma on its Share Placing

Kirkland & Ellis represented Ascletis Pharma Inc. (Ascletis Pharma, Stock Code: 1672) on its placing of 69,256,000 shares. The Placing was announced on February 3, 2026 and completed on February 10, 2026. Citigroup Global Markets Limited acts as its sole placing agent.

The net proceeds (after deducting the commissions and estimated expenses) from the Placing are expected to be approximately HK$835.3 million in aggregate.

Read the transaction announcement 

The Kirkland team included capital markets lawyers Mengyu Lu, Justin Zhou, Sierra Tao and Claire Chen.